About: Nelotanserin

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Nelotanserin (former developmental code name APD-125) is a drug developed by Arena Pharmaceuticals which acts as an inverse agonist on the serotonin receptor subtype 5-HT2A and was under development for the treatment of insomnia. It was shown to be effective and well tolerated in clinical trials, but development was halted in December 2008 because the substance did not meet the trial's effectiveness endpoints. Research continues on newer analogues which may potentially be more successful. More recently, nelotanserin has been repurposed for the treatment of Lewy body disease. As of 2017, it is in phase II clinical trials for this indication.

Property	Value
dbo:abstract	Nelotanserin (former developmental code name APD-125) is a drug developed by Arena Pharmaceuticals which acts as an inverse agonist on the serotonin receptor subtype 5-HT2A and was under development for the treatment of insomnia. It was shown to be effective and well tolerated in clinical trials, but development was halted in December 2008 because the substance did not meet the trial's effectiveness endpoints. Research continues on newer analogues which may potentially be more successful. More recently, nelotanserin has been repurposed for the treatment of Lewy body disease. As of 2017, it is in phase II clinical trials for this indication. (en)
dbo:casNumber	839713-36-9
dbo:fdaUniiCode	4ZA73QEW2P
dbo:kegg	D09645
dbo:pubchem	11683556
dbo:thumbnail	wiki-commons:Special:FilePath/Nelotanserin_structure.png?width=300
dbo:wikiPageID	30454919 (xsd:integer)
dbo:wikiPageLength	5084 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1084240154 (xsd:integer)
dbo:wikiPageWikiLink	dbc:Fluoroarenes dbc:Organobromides dbc:Phenol_ethers dbc:Ureas dbr:Oral_administration dbr:Lewy_body_disease dbr:Clinical_trial dbr:Drug dbr:5-HT2A_receptor dbc:5-HT2A_antagonists dbr:Inverse_agonist dbr:Arena_Pharmaceuticals dbr:Insomnia dbr:Phases_of_clinical_research dbr:Serotonin_receptor
dbp:atcPrefix	none (en)
dbp:br	1 (xsd:integer)
dbp:c	18 (xsd:integer)
dbp:casNumber	839713 (xsd:integer)
dbp:chemspiderid	9858284 (xsd:integer)
dbp:f	2 (xsd:integer)
dbp:h	15 (xsd:integer)
dbp:iupacName	1 (xsd:integer)
dbp:kegg	D09645 (en)
dbp:n	4 (xsd:integer)
dbp:o	2 (xsd:integer)
dbp:pubchem	11683556 (xsd:integer)
dbp:routesOfAdministration	dbr:Oral_administration
dbp:smiles	Brc1cnnc1-c2ccNCNc3ccccc3F (en)
dbp:stdinchi	1 (xsd:integer)
dbp:stdinchikey	COSPVUFTLGQDQL-UHFFFAOYSA-N (en)
dbp:synonyms	APD-125 (en)
dbp:unii	4 (xsd:integer)
dbp:verifiedfields	changed (en)
dbp:verifiedrevid	424750865 (xsd:integer)
dbp:watchedfields	changed (en)
dbp:width	250 (xsd:integer)
dbp:wikiPageUsesTemplate	dbt:Drugbox dbt:Nervous-system-drug-stub dbt:Reflist dbt:Serotonin_receptor_modulators dbt:Short_description dbt:Cascite dbt:Chemspidercite dbt:Fdacite dbt:Stdinchicite
dcterms:subject	dbc:Fluoroarenes dbc:Organobromides dbc:Phenol_ethers dbc:Ureas dbc:5-HT2A_antagonists
gold:hypernym	dbr:Drug
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 yago:WikicatMolecularFormulas yago:WikicatUreas yago:Abstraction100002137 yago:Chemical114806838 yago:Communication100033020 yago:Compound114818238 yago:Element114840755 yago:Formula106816935 yago:Material114580897 yago:Matter100020827 yago:Message106598915 yago:MolecularFormula106817173 yago:OrganicCompound114727670 yago:Part113809207 yago:PhysicalEntity100001930 yago:Quintessence114847103 yago:Relation100031921 dbo:Drug yago:Statement106722453 yago:Substance100019613 yago:Urea115085472 yago:WikicatPhenolEthers
rdfs:comment	Nelotanserin (former developmental code name APD-125) is a drug developed by Arena Pharmaceuticals which acts as an inverse agonist on the serotonin receptor subtype 5-HT2A and was under development for the treatment of insomnia. It was shown to be effective and well tolerated in clinical trials, but development was halted in December 2008 because the substance did not meet the trial's effectiveness endpoints. Research continues on newer analogues which may potentially be more successful. More recently, nelotanserin has been repurposed for the treatment of Lewy body disease. As of 2017, it is in phase II clinical trials for this indication. (en)
rdfs:label	Nelotanserin (en)
owl:sameAs	freebase:Nelotanserin yago-res:Nelotanserin wikidata:Nelotanserin dbpedia-sh:Nelotanserin dbpedia-sr:Nelotanserin https://global.dbpedia.org/id/4sPRT
prov:wasDerivedFrom	wikipedia-en:Nelotanserin?oldid=1084240154&ns=0
foaf:depiction	wiki-commons:Special:FilePath/Nelotanserin_structure.png
foaf:isPrimaryTopicOf	wikipedia-en:Nelotanserin
is dbo:wikiPageRedirects of	dbr:C18H15BrF2N4O2
is dbo:wikiPageWikiLink of	dbr:C18H15BrF2N4O2 dbr:5-HT2A_receptor dbr:Arena_Pharmaceuticals dbr:Axovant_Sciences dbr:List_of_drugs:_Nb–Nh
is foaf:primaryTopic of	wikipedia-en:Nelotanserin